RECRUITING

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)Peritoneal Carcinomatosis pancreatic adenocarcinoma pancreatic ductal adenocarcinoma PDAC metastatic NALIRIFOX intraperitoneal chemotherapy intraperitoneal paclitaxel circulating tumor DNA (ctDNA)peritoneal cell-free DNA

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This goal of this clinical trial is to learn whether the drug combination of intraperitoneal paclitaxel (chemotherapy given directly into the abdominal cavity) and intravenous NALIRIFOX (chemotherapy given into a vein, including fluorouracil, leucovorin, oxaliplatin, and liposomal irinotecan) is safe and works in adults with pancreatic cancer that has spread to the peritoneum. The main questions it aims to answer are: * Are people with pancreatic cancer able to tolerate the combination drug regimen? * How well does the combination drug regimen work to treat pancreatic cancer? Participants will: * Obtain a port that goes into the abdomen to deliver intraperitoneal paclitaxel (called an intraperitoneal catheter) * Receive treatment with intravenous NALIRIFOX once every 2 weeks and intraperitoneal paclitaxel on days 1 and 8 of each 14-day cycle * Visit the clinic with each treatment for checkups and laboratory testing * Have imaging scans and blood lab testing to determine response to treatment * Have abdominal fluid lab testing that may help determine if the cancer is responding to treatment * Fill out questionnaires to see how the treatment affects how participants feel and function * Continue follow up after treatment ends to track survival Some participants may be able to have surgery later if the cancer responds well. This is called conversion surgery. To be eligible for surgery, the cancer must have shrunk or stayed the same, peritoneal fluid (from the abdomen) must no longer show cancer cells, and a tumor marker called CA 19-9 must decrease or return to normal. The decision to do surgery will depend on the treating surgeon. By testing this new treatment strategy, researchers hope to find a safer and more effective way to treat people with pancreatic cancer that has spread to the abdomen. If successful, this approach may lead to longer survival, better quality of life, and more people becoming eligible for surgery.

Official Title

Intraperitoneal Paclitaxel With Standard Systemic NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis: Prospective Pilot Trial

Quick Facts

Study Start:2025-12-01

Study Completion:2030-07-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07030283

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Provision to sign and date the consent form. 2. Stated willingness to comply with all study procedures and be available for the duration of the study. 3. Be age 18 years or older. 4. Histologically or cytologically confirmed pancreatic adenocarcinoma with histologically or cytologically proven seeding in the peritoneal cavity without metastasis to other organs. 5. Primary tumor that is resectable, borderline resectable, or locally advanced per NCCN classification. 6. PCI score ≤ 8. 7. ECOG performance status of 0 or 1 8. Prior treatment for 0-4 months with FOLFIRINOX, modified FOLFIRINOX, or NALIRIFOX and able to receive additional treatment per investigator opinion 9. Adequate biological parameters as evidenced by all of the following blood counts: * Absolute neutrophil count (ANC) \>/= 1,500 per cubic millimeter without the use of hematopoietic growth factors within 14 days prior to screening * Platelet count \>/= 75,000 per cubic millimeter * Hemoglobin \> 9 g/dL 10. Adequate hepatic function as evidenced by: * Serum total bilirubin ≤ 1.5x ULN (biliary drainage is allowed for biliary obstruction), and * AST and ALT ≤ 3 x ULN 11. Adequate renal function as evidenced by serum creatinine \<1.5 x ULN	1. Prior treatment of pancreatic cancer in the metastatic setting with surgery or investigational therapy (Note: biliary drainage, diagnostic laparoscopy/laparotomy, and duodenal stenting is allowed). 2. Evident distant metastatic disease outside of the peritoneal cavity. 3. Extensive metastatic disease in peritoneal cavity (PCI\>8). 4. Known disease progression with any prior chemotherapy. 5. Known hypersensitivity to paclitaxel or other liposomal products. 6. Current use of strong CYP2C8 inhibitors or inducers, or presence of any other contraindications for paclitaxel. 7. Known UGT1A1 deficiency or DPD deficiency. 8. Neuropathy Grade 2 or higher 9. Known active COVID infection with symptoms. 10. Has ever received or is currently receiving radiation for pancreatic cancer treatment. 11. Receipt of live, attenuated vaccine within 30 days prior the first dose of Intraperitoneal paclitaxel. (Note: enrolled patients should not receive live vaccines during the study and up to 30 days after the last dose of intraperitoneal paclitaxel). 12. Known positive test results for human immunodeficiency (HIV) or patients with chronic or active hepatitis B or C. Patients who have a history of hepatitis B or C who have undetectable HBV DNA or HCV RNA after anti-viral therapy may be enrolled. 13. Active infection during screening visits or on the day of treatment, which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome. 14. Any other medical or social condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results. 15. Pregnant or breast feeding; females of child-bearing potential must test negative for pregnancy within 7 days prior to C1D1. Both male and female patients of reproductive potential must agree to use a highly effective method of birth control during the study and for 9 months following the last dose of both IP PTX and IV NALIRIFOX. 16. Histologies other than adenocarcinoma, such as neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma. 17. Patients who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening.

Inclusion Criteria

Exclusion Criteria

1. Provision to sign and date the consent form.
2. Stated willingness to comply with all study procedures and be available for the duration of the study.
3. Be age 18 years or older.
4. Histologically or cytologically confirmed pancreatic adenocarcinoma with histologically or cytologically proven seeding in the peritoneal cavity without metastasis to other organs.
5. Primary tumor that is resectable, borderline resectable, or locally advanced per NCCN classification.
6. PCI score ≤ 8.
7. ECOG performance status of 0 or 1
8. Prior treatment for 0-4 months with FOLFIRINOX, modified FOLFIRINOX, or NALIRIFOX and able to receive additional treatment per investigator opinion
9. Adequate biological parameters as evidenced by all of the following blood counts:
* Absolute neutrophil count (ANC) \>/= 1,500 per cubic millimeter without the use of hematopoietic growth factors within 14 days prior to screening
* Platelet count \>/= 75,000 per cubic millimeter
* Hemoglobin \> 9 g/dL
10. Adequate hepatic function as evidenced by:
* Serum total bilirubin ≤ 1.5x ULN (biliary drainage is allowed for biliary obstruction), and
* AST and ALT ≤ 3 x ULN
11. Adequate renal function as evidenced by serum creatinine \<1.5 x ULN

1. Prior treatment of pancreatic cancer in the metastatic setting with surgery or investigational therapy (Note: biliary drainage, diagnostic laparoscopy/laparotomy, and duodenal stenting is allowed).
2. Evident distant metastatic disease outside of the peritoneal cavity.
3. Extensive metastatic disease in peritoneal cavity (PCI\>8).
4. Known disease progression with any prior chemotherapy.
5. Known hypersensitivity to paclitaxel or other liposomal products.
6. Current use of strong CYP2C8 inhibitors or inducers, or presence of any other contraindications for paclitaxel.
7. Known UGT1A1 deficiency or DPD deficiency.
8. Neuropathy Grade 2 or higher
9. Known active COVID infection with symptoms.
10. Has ever received or is currently receiving radiation for pancreatic cancer treatment.
11. Receipt of live, attenuated vaccine within 30 days prior the first dose of Intraperitoneal paclitaxel. (Note: enrolled patients should not receive live vaccines during the study and up to 30 days after the last dose of intraperitoneal paclitaxel).
12. Known positive test results for human immunodeficiency (HIV) or patients with chronic or active hepatitis B or C. Patients who have a history of hepatitis B or C who have undetectable HBV DNA or HCV RNA after anti-viral therapy may be enrolled.
13. Active infection during screening visits or on the day of treatment, which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome.
14. Any other medical or social condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
15. Pregnant or breast feeding; females of child-bearing potential must test negative for pregnancy within 7 days prior to C1D1. Both male and female patients of reproductive potential must agree to use a highly effective method of birth control during the study and for 9 months following the last dose of both IP PTX and IV NALIRIFOX.
16. Histologies other than adenocarcinoma, such as neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma.
17. Patients who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening.

Contacts and Locations

Study Contact

Puja Gupta Poddar

CONTACT

720-278-0236

puja.guptapoddar@cuanschutz.edu

Principal Investigator

Alexis Leal, MD

PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Study Locations (Sites)

University of Colorado Cancer Center

Aurora, Colorado, 80045

United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

Alexis Leal, MD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-12-01

Study Completion Date2030-07-01

Study Record Updates

Study Start Date2025-12-01

Study Completion Date2030-07-01

Terms related to this study

Keywords Provided by Researchers

Peritoneal Carcinomatosis
pancreatic adenocarcinoma
pancreatic ductal adenocarcinoma
PDAC
metastatic
NALIRIFOX
intraperitoneal chemotherapy
intraperitoneal paclitaxel
circulating tumor DNA (ctDNA)
peritoneal cell-free DNA

Additional Relevant MeSH Terms

Pancreatic Ductal Adenocarcinoma (PDAC)